Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial

The goal of this double-blind, randomized, placebo-controlled study is to evaluate whether oxybutynin chloride extended-release tablets can improve early continence recovery after robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer. The main questions it aims to answer are: \[Does oxybutynin chloride improve continence recovery after RARP compared to a placebo?\] \[What are the predictors of continence recovery?\] Researchers will compare the treatment group (oxybutynin chloride 10 mg/day) with the control group (placebo) to assess differences in continenc

Trial Details

NCT ID
NCT06966778
Phase
NA
Sponsor
National Taiwan University Hospital
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Oxybutynin chloride extended-release tablets 5mg/tab, 2 tab, PO, qd.
  • Placebo (2 tab), PO, qd.
Locations (sample)
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Diagnosis: Patients with localized prostate cancer who are scheduled to undergo robot-assisted radical prostatectomy (RARP).
  • Age: Participants must be 18 years or older, with no upper age limit.
  • Consent: Participants must provide written informed consent before undergoing any study procedures.
  • Ability to Follow Protocol: Participants must be able to follow the protocol procedures throughout the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →